Pathogenesis and prognostication in acute lymphoblastic leukemia
Tsila Zuckerman1,3* and Jacob M. Rowe2,3

Addresses: 1Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, 8 Ha'Aliya Street, Haifa 31096, Israel; 2Department of Hematology, Shaare Zedek Medical Center, 12 Bayit Street, Jerusalem 91031, Israel; 3Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Efron Street, Haifa 31096, Israel

* Corresponding author: Tsila Zuckerman (t_zuckerman@rambam.health.gov.il)

F1000Prime Reports 2014, 6:59 (doi:10.12703/P6-59)
All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/6/59

Abstract
The process of lymphoid maturation is tightly controlled by the hierarchical activation of transcription factors and selection through functional signal transduction. Acute lymphoblastic leukemia (ALL) represents a group of B/T-precursor-stage lymphoid cell malignancies arising from genetic alterations that block lymphoid differentiation and drive aberrant cell proliferation and survival. With recent advances in next-generation sequencing, we are discovering new mutations affecting normal lymphopoiesis and the significance of cooperating mutations, as well as epigenetic alterations. The data obtained in this way aids in the evaluation of prognosis in the individual patient but, importantly, also in incorporating targeted therapy appropriate for the mutational abnormality.

Introduction
ALL arises from hematopoietic precursors of the lymphoid lineage. It is the most common leukemia in pediatrics, accounting for up to 80% of leukemias in this group and 20% of leukemias in adults. With the advances in cytogenetic (and especially molecular) techniques over the last two decades, our understanding of the biology and pathogenesis of leukemia has progressed tremendously. This progression is now in the process of being translated into better biological prognostication, detection of residual disease and tailored/targeted therapy [1]. The following review will focus on recent findings in the cytogenetic and molecular alterations associated with ALL pathogenesis and its prognostic significance. However, despite the increasing awareness of cytogenetic and mutational factors for prognosis, it is important to remember that, on an individual basis, many of these favorable or unfavorable factors may be superseded by the detection or absence of minimal residual disease — a tool increasingly used to tailor patient therapy.

Pathogenesis
Lymphoid cells are derived from pluripotent hematopoietic stem cells in the bone marrow, through stepwise maturation. In the case of B cell development, this includes development initiated at the level of lymphoid-primed multipotent progenitors, common lymphoid progenitors, pro-B cells, pre-B cells, and mature B cells. This maturation process is tightly controlled by the hierarchical activation of transcription factors and selection through functional signal transduction [2].

ALL represents a group of B/T-precursor-stage lymphoid cell malignancies (arising from genetic insults) that blocks lymphoid differentiation and drives aberrant cell proliferation and survival. The clinical heterogeneity of the disease course and outcome, especially when comparing pediatric and adult populations, reflects different biological subtypes.

It has long been known that ALL is characterized by gross numerical and structural chromosomal abnormalities, including hyperdiploidy (>50 chromosomes), hypodiploidy (<44 chromosomes), translocations t([12;21], [1;19], [9;22], [4;11]) and rearrangements (MYC, MLL). However, several observations indicate that these lesions alone are insufficient to induce leukemia and cooperating lesions are required. As an example, rearrangements such as...
as t(12;21), ETV6-RUNX1, comprising 22% of pediatric ALL, are present years before the development of leukemia [3,4]. Many of the genes involved encode proteins with key roles in lymphoid development. It is suggested that the initial event confers self-renewal coupled with mutation, leading to developmental arrest and a secondary cooperative event in cell cycle regulation, tumor suppression and chromatin modification, eventually leading to establishment of the leukemic clone [5,6].

The determination of prognosis was based until very recently on classical G banding cytogenetics. Several reports describe the outcome based on cytogenetic analysis, in large cohorts of pediatric and adult ALL patients, respectively [3,7-9].

Advances in genomic techniques over the last two decades have enabled better genetic profiling of the leukemic clone. The techniques used include three main categories. Firstly, cytogenetic studies with conventional G banding as well as fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) analysis have identified structural chromosomal alterations. Secondly, genome-wide profiling uses array-based comparative genomic hybridization or single nucleotide polymorphism microarrays and gene expression profiling. Thirdly, sequencing studies use whole-genome sequencing, transcriptome sequencing and/or whole-exome sequencing to more comprehensively define the genomic landscape of these diseases.

ALL genomes typically harbor fewer structural genetic alterations than many solid tumors. More than 50 recurring regions of DNA copy number alterations have been identified, which are commonly focal deletions, limited to one or few genes involved in normal lymphoid development: transcriptional regulators of lymphoid development (PAX5, IKZF1, EBF1, LEF1), tumor suppressors (CDKN2A, CDKN2B, RB1, TP53), lymphoid signaling genes (BTLA, CD200, TOX), transcriptional regulators and coactivators (TBL1XR1, ERG), as well as regulators of chromatin structure and epigenetic regulators (CTCF, CREBBP). T-lineage ALL is characterized by activating mutations of NOTCH1 and rearrangements of transcription factors TLX1 (HOX11), TLX3 (HOX11L2), LYL1, TAL1, and MLL [10].

Sequencing of the full spectrum of ALL subtypes has shown that the alteration of multiple cellular pathways, including cytokine receptor and Ras signaling, tumor suppression, lymphoid development, and epigenetic regulation, are typical events in different ALL subtypes.

**Genomic prognostication in ALL**

Not all genetic lesions have prognostic implications. Those relevant to prognosis will be reviewed here. Table 1 details major known abnormalities in B- and T-ALL and their prognostic significance.

Recent discoveries in the genomic landscape of ALL and its influence on prognosis include: the BCR-ABL1-like ALL, cytokine receptor-like factor 2 (CRLF2) overexpression and Janus kinase (JAK) mutations, hypodiploid ALL and T-ALL [1,11].

**BCR-ABL1-like B-ALL and IKZF1 alterations**

BCR-ABL1-like ALL carries the gene expression signature similar to that of BCR-ABL1 ALL, while not harboring the BCR-ABL1 translocation. More than 80% of patients with BCR-ABL1-like ALL have abnormalities in genes involved in B-cell development, such as IKZF1, PAX5 and VPREB1. The prevalence of BCR-ABL1-like ALL is approximately 15% in pediatric B-cell ALLs and it was found to be associated with inferior outcome (5-year event-free survival <60%), as is BCR-ABL1 ALL [12].

The lymphoid transcription factor gene IKZF1 encodes IKAROS, the founding member of a family of zinc finger transcription factors that is required for the development of all lymphoid lineages [13]. The IKZF1 alterations

| Cytogenetic abnormality | Target gene | Frequency in pediatrics % | Frequency in adults % | Prognosis |
|------------------------|-------------|--------------------------|-----------------------|----------|
| t(1;19)(q23;p13)       | E2A-PBX1    | 4-6                      | 2-3                   | standard |
| t(9;22)(q34;q11)       | BCR-ABL1    | 3-5                      | 25-30                 | unfavorable |
| t(4;11)(q21;q23)       | MLL-AF4     | 2-3                      | 5-7                   | unfavorable |
| High hyperdiploid      |             | 20-30                    |                       | favorable |
| Hypodiploid            |             | 5-6                      | 3                     | unfavorable |
| t(12;21)               | ETV6-RUNX1  | 25                       |                       | favorable |
| T-ALL                  | TCR         |                          |                       | favorable |
| T(7;14)(14q34 or 7p14) | Non-TCR(NOTCH1, HOX11, JAK1) | 60%                     |           | favorable |

Abbreviations: ALL, Acute lymphoblastic leukemia.
observed in ALL are mainly deletions that result in a loss of function. **IKZF1** alterations are present in more than 70% of cases of BCR-ABL1 ALL and are associated with a poor outcome both in BCR-ABL1+ and BCR-ABL1− ALL [11,14].

In a recent large study of over 1000 pediatric patients from four collaborative groups, BCR-ABL1-like and **IKZF1** alterations were reported in 16% and 17% of patients, respectively, and in 53% and 40%, respectively, of B-ALL cases lacking known abnormalities, such as hyperdiploidy, ETV6-RUNX1, TCF3 and MLL rearrangement. Patients with either BCR-ABL1-like or **IKZF1** alterations were found to have a statistically significantly higher relapse rate compared to other genetic groups, requiring treatment modification [15].

**CRLF2 over expression and JAK mutations**

CRLF2, also known as thymic stromal-derived lymphopoietin receptor, is a type I cytokine receptor. CRLF2 forms a heterodimeric complex with IL-7Rα in a functional signaling unit. CRLF2 levels are markedly elevated in a subset of B-ALL cases caused by translocation or deletions. The frequency of CRLF2 alterations in B-ALL depends on the patient cohort. P2RY8-CRLF2 fusion is 7% in pediatric patients with B-ALL, but occurs in up to 50% of B-ALL cases associated with Down syndrome.

More importantly, aberrant CRLF2 expression is frequent in B-ALL cases that lack recurrent B-ALL-associated translocations [16].

Up to half of BCR-ABL1-like cases harbor rearrangement of CRLF2 resulting in over-expression of CRLF2 on the surface of lymphoid blasts that may be detected by immunophenotyping. Additionally, approximately half of CRLF2-rearranged cases harbor concomitant activating mutations of the JAK genes **JAK1** and **JAK2** [17]. The JAK/ signal transducers and activators of transcription (STAT) pathway mediates signaling from cytokine, chemokine, and growth factor receptors via the JAK non-receptor tyrosine kinases and the STAT family of transcription factors [18]. These alterations result in activation of JAK-STAT signaling that may be amenable to therapy with JAK inhibitors such as ruxolitinib, and this is currently being explored as a therapeutic strategy. Ongoing next-generation sequencing studies in childhood and adult ALL are designed to define the repertoire of kinase-activating alterations in BCR-ABL1-like ALL and to develop clinical trials aimed at directing patients with BCR-ABL1-like ALL to appropriate tyrosine-kinase inhibitor (TKI) therapy [11].

**Hypodiploid ALL**

Two subtypes of hypodiploid ALL have been described according to the severity of aneuploidy: near-haploid cases with 24 to 31 chromosomes and low-hypodiploid cases with 32 to 39 chromosomes.

Recently, an analysis of a large cohort of more than 120 hypodiploid pediatric ALL patients has demonstrated that near-haploid and low-hypodiploid ALL have distinct transcriptomic signatures and submicroscopic genetic alterations [19]. The majority of near-haploid cases harbor alterations targeting receptor tyrosine kinase signaling and Ras signaling (71%) and the lymphoid transcription factor gene **IKZF3** (13%). In contrast, low-hypodiploid ALLs with 32–39 chromosomes are characterized by alterations in **TP53** (91.2%), **IKZF2** (53%) and **RB1** (41%). Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs might be used for this aggressive form of leukemia [11].

**T-ALL**

T-lineage ALL is characterized by an older age of onset, male sex preponderance, and inferior outcome in comparison with B-ALL [20]. Recently, next-generation sequencing identified sequence mutations and, less commonly, deletion of **PHF6** in 16% and 38% of childhood and adult T-ALL cases, respectively [9]. The role of **PHF6** in leukemogenesis is poorly understood, but the loss-of-function alterations suggest that **PHF6** is a tumor suppressor.

Early T-cell precursor ALL is an aggressive subtype of immature leukemia that accounts for a high proportion of T-ALL treatment failures. Recent studies found this entity to be associated with loss-of-function mutations in hematopoietic regulators (GATA3, **IKZF1**, RUNX1, ETV6), gain-of-function mutations in Ras, FLT3, JAK, and IL7R, and also inactivating mutations in epigenetic regulators (EZH2, SUZ12, EED, SETD2, DNMT3A) [21]. The mutational spectrum of this ALL subtype is similar to that observed in myeloid leukemias, and comparison of its transcriptional profile with those of normal human hematopoietic progenitors showed significant similarity to hematopoietic stem and early myeloid progenitors. Thus, the T-cell precursor ALL is likely to represent part of a spectrum of immature, stem cell-like leukemias. Epigenetic modifiers and agents targeting JAK-STAT signaling are currently being explored [22,23].

In addition to acquired mutation, an inherited susceptibility to develop ALL was found to be associated with a specific genome composition. **ARID5B**, **IKZF1**, **CEBP3**, and **BMI1-PIP4K2A** variants cumulatively conferred a strong predisposition to ALL, with children carrying six
to eight copies of risk alleles at a nine-fold higher ALL risk relative to those carrying zero to one risk allele at these four single nucleotide polymorphisms [24].

**Conclusion**

Progress in sequencing methods has advanced our understanding of the molecular basis of lymphoid neoplasms by implicating new genes and core pathways, refining classification schema, and identifying new targets for therapeutic intervention. It is important to comprehend that this picture is continually evolving and is expected to change as better molecular techniques and more data accumulate.

**Abbreviations**

ALL, acute lymphoblastic leukemia; CRLF2, cytokine receptor-like factor 2; JAK, Janus kinase; PI3K, phosphoinositide 3-kinase; STAT, signal transducers and activators of transcription.

**Disclosures**

The authors declare that they have no disclosures.

**References**

1. Asselin, BL, Gaynon, P, Whidack, JA. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. *Curr Opin Oncol* 2013; 25(Suppl 3):S1-13; quiz S14-6.

2. Zhou Y, You M, Young KH, Lin P, Lu G, Medeiros LJ, Bueso-Ramos CE. Advances in the molecular pathobiology of B-lymphoblastic leukemia. *Hum Pathol* 2012; 43:1347-62.

3. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. *Lancet Oncol* 2010; 11:429-38.

4. Ma Y, Dobbins SE, Sherborne AL, Chubb D, Galbiati M, Cazzaniga G, Micalizzi C, Tearle R, Lloyd AL, Hain R, Greaves M, Houlston RS. Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. *Proc Natl Acad Sci USA* 2013; 110:7429-33.

5. Lo Nigro L. Biology of childhood acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* 2013; 35:245-52.

6. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. *Blood* 2003; 102:2321-33.

7. Figueroa ME, Chen S, Andersson AK, Phillips LA, Li Y, Sotzen J, Kundu M, Downing JR, Melnick A, Mullighan CG. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. *J Clin Invest* 2013; 123:3099-111.

8. Moorman AV, Harrison CJ, Buck, Georgina AN, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paieata E, Tallman MS, Lizow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood* 2007; 109: 3189-97.

9. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengliné E, Gunzburg N de, Payet-Borinet D, Uhermitte L, Mossafa H, Lhérétier V, Bond J, Huguet F, Buzyn A, Leguy C, Cahn J, Thomas X, Chalandon Y, Delanoyon A, Bonnatto C, Maury S, Nadel B, Macintyre R, Ifrah N, Dombrert H, Asnafi V. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. *J Clin Oncol* 2013; 31:4333-42.

10. Mullighan CG. The molecular genetic makeup of lymphoblastic leukemia. *Hematol Am Soc Hematol Educ Program* 2012; 2012:350-9.

11. Mullighan CG. Genome sequencing of lymphoid malignancies. *Blood* 2013; 122:3899-907.

12. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau, Michelle M, Pui C, Relling MV, Shurtleff SA, Downing JR. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature* 2008; 453:110-4.

13. Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Collini D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidi C, Poloni S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foa R. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *J Clin Oncol* 2009; 27:5202-7.

14. Mullighan CG, Su X, Zhang J, Radtke I, Phillips, Letha AA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen I, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui C, Smith M, Hunger SP, Willman CL, Downing JR. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med* 2009; 360:470-80.

15. van der Veer, Arian, Waanders E, Pieters R, Willemsen ME, Van Reijmersdal, Simon V, Reijmersdal, Simon V,Russell LJ, Harrison CJ, Evans WE, van der Velden, Vincent HJ, Hoogerbrugge PM, van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Knakaldani L, Raptopoulos D, De Groot-Kruiseman, Hester A, Sonneveld E, Kuiper RP, Den Boer, Monique L: Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. *Blood* 2013; 122:2622-9.

16. Russell LJ, Capasso M, Vater I, Aksalata T, Bernard OA, Calasan M, Chandrasekaran T, Chapiao E, Gask S, Griffiths M, Guttridge DS, Haferlakh C, Harder L, Heidenreich O, Irving J, Kearnley L, Nguyen Khac F, Machado L, Minto L, Majad A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab C, Tonnies H, Dyer, Martin JS, Siebert R, Harrison CJ. Deregulated expression of cytokine receptor
gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-98.

17. Scott LM: Lymphoid malignancies: Another face to the Janus kinases. Blood Rev 2013, 27:63-70.

18. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasant SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen I, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL: JAK mutations in high-risk childhood acute lymphoblastic leukaemia. Proc Natl Acad Sci USA 2009, 106:9414-8.

19. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen S, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenburg C, Baker S, Pei D, Cheng C, Huether R, et al.: The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013, 45:242-52.

20. Paganin M, Ferrando A: Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011, 25:83-90.

21. Haydu JE, Ferrando AA: Early T-cell precursor acute lymphoblastic leukemia. Curr Opin Hematol 2013, 20:369-73.

22. Neumann M, Heesch S, Gökbuget N, Schwartz S, Schlee C, Benlasfer O, Farhadi-Sartangi N, Thibaut J, Burmeister T, Hoelzer D, Hofmann W, Thiel E, Baldus CD: Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2012, 2:e55.

23. Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksenzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Bruggemann M, Hofmann W, Hecht J, Bohlender SK, Greif PA, Baldus CD: Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013, 121:4749-52.

24. Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C, Pei D, Scheet P, Burchard EG, Eng C, Huntsman S, Torgerson DG, Dean M, Winick NJ, Martin PL, Camitta BM, Bowman WP, Willman CL, Carroll WL, Mullighan CG, Bhojwani D, Hunger SP, Pui C, Evans WE, Relling MV, Loh ML, Yang JJ: Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013, 105:733-42.